Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
First Claim
1. A method of eliciting an immune response in a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that aberrantly express a peptide in the patient, wherein said peptide consists of the amino acid sequence of SMLGEEIQL (SEQ ID NO:
- 2), wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of treating a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, BRCA, melanoma, and/or uterine cancer.
-
Citations
13 Claims
-
1. A method of eliciting an immune response in a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that aberrantly express a peptide in the patient, wherein said peptide consists of the amino acid sequence of SMLGEEIQL (SEQ ID NO:
- 2), wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
Specification